Drug Profile
Adalimumab biosimilar - Merck/Samsung Bioepis
Alternative Names: adalimumab-bwwd; ADALLOCE; HADLIMA; Hadlima; Imraldi; SB-5Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Samsung Bioepis
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
Most Recent Events
- 26 Oct 2023 Organon launches adalimumab biosimilar (HADLIMA™) in a high-concentration, citrate free (40 mg/0.4 mL) version for the treatment of Ankylosing spondylitis, Crohn's disease (In adults), Hidradenitis suppurativa (In adults, In adolescents), Juvenile rheumatoid arthritis, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, Uveitis (In adults, In adolescents, In children) in Canada
- 01 Jul 2023 Launched for Ankylosing spondylitis in USA (SC)
- 01 Jul 2023 Launched for Crohn's disease in USA (SC)